MX2022000489A - Formulacion de larga duracion que contiene rivastigmina y metodo para prepararla. - Google Patents

Formulacion de larga duracion que contiene rivastigmina y metodo para prepararla.

Info

Publication number
MX2022000489A
MX2022000489A MX2022000489A MX2022000489A MX2022000489A MX 2022000489 A MX2022000489 A MX 2022000489A MX 2022000489 A MX2022000489 A MX 2022000489A MX 2022000489 A MX2022000489 A MX 2022000489A MX 2022000489 A MX2022000489 A MX 2022000489A
Authority
MX
Mexico
Prior art keywords
microspheres
long
formulation containing
injection formulation
rivastigmine
Prior art date
Application number
MX2022000489A
Other languages
English (en)
Inventor
Heeyong Lee
Eunyoung Seol
Juhan Lee
Yeonkyeong Lee
Donghyun Park
Heekyoung Choe
Original Assignee
G2Gbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G2Gbio Inc filed Critical G2Gbio Inc
Publication of MX2022000489A publication Critical patent/MX2022000489A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Abstract

La presente invención se relaciona a una microesfera de liberación sostenida para formulaciones inyectables de larga duración que comprenden uno o más ingredientes activos seleccionados del grupo que consiste de rivastigmina y sales deficientemente solubles farmacéuticamente aceptables de la misma y un polímero biodegradable, y una formulación inyectable de larga duración para prevenir o tratar enfermedad de Alzheimer que comprende la misma y un método para preparar la microesfera, y esta puede reducir los efectos secundarios del tracto gastrointestinal del paciente, que frecuentemente se observan en el agente de administración oral convencionales, e incrementar la adaptabilidad de la toma de medicina, para de esta manera maximizar el efecto terapéutico, al proporcionar una formulación inyectable de larga duración que comprende una microesfera de liberación sostenida de rivastigmina, que tiene un alto contenido mientras que controla de manera efectiva la liberación del fármaco repentina inicial.
MX2022000489A 2019-07-12 2020-07-13 Formulacion de larga duracion que contiene rivastigmina y metodo para prepararla. MX2022000489A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190084775 2019-07-12
PCT/KR2020/009221 WO2021010719A1 (ko) 2019-07-12 2020-07-13 리바스티그민을 포함하는 장기지속형 제제 및 이의 제조방법

Publications (1)

Publication Number Publication Date
MX2022000489A true MX2022000489A (es) 2022-02-03

Family

ID=74211043

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000489A MX2022000489A (es) 2019-07-12 2020-07-13 Formulacion de larga duracion que contiene rivastigmina y metodo para prepararla.

Country Status (11)

Country Link
US (1) US20220257518A1 (es)
EP (1) EP3998065A4 (es)
JP (2) JP7437074B2 (es)
KR (4) KR20210007924A (es)
CN (1) CN114126592A (es)
AU (1) AU2020312361B2 (es)
BR (1) BR112022000413A2 (es)
CA (1) CA3143471C (es)
MX (1) MX2022000489A (es)
WO (1) WO2021010719A1 (es)
ZA (1) ZA202201465B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210158232A (ko) * 2020-06-23 2021-12-30 주식회사 아울바이오 치매치료를 위한 장기지속형 주사제
TW202304862A (zh) * 2021-03-26 2023-02-01 大陸商上海博志研新藥物技術有限公司 哌馬色林藥用鹽、製備方法、含其的藥物組合物及應用
CN113877000B (zh) * 2021-10-13 2023-01-24 科笛生物医药(无锡)有限公司 注射用微球组合物及其应用
WO2023249464A1 (ko) * 2022-06-23 2023-12-28 주식회사 지투지바이오 약물과 파모산을 함유하는 서방성 미립구
WO2023249465A1 (ko) * 2022-06-23 2023-12-28 주식회사 지투지바이오 엔테카비르를 포함하는 장기지속성 미립구 제제 및 이의 제조방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0669128T3 (da) * 1992-11-17 2000-06-19 Yoshitomi Pharmaceutical Sustained-release mikrosfære indeholdende antipsykotikum og fremgangsmåde til at fremstille samme
ES2791698T3 (es) * 2006-12-18 2020-11-05 Takeda Pharmaceuticals Co Composición de liberación sostenida y método para producir la misma
CN101708164A (zh) 2009-12-18 2010-05-19 苏州大学 一种卡巴拉汀缓释微球及其制备方法
KR20120011344A (ko) * 2010-07-21 2012-02-08 에스케이케미칼주식회사 고분자 미립구의 제조방법 및 그 방법에 의해 제조된 고분자 미립구
KR101424163B1 (ko) * 2010-12-24 2014-08-01 주식회사 삼양바이오팜 수난용성 약물 함유 서방성 마이크로입자 및 그 제조방법
WO2013078608A1 (en) * 2011-11-29 2013-06-06 Ziqiang Gu Donepezil pamoate and methods of making and using the same
KR101307729B1 (ko) * 2012-11-19 2013-09-11 에스케이케미칼주식회사 초기 약물 방출이 감소된 고분자 미립자를 포함하는 주사용 조성물 및 이의 제조방법
KR101811797B1 (ko) * 2013-04-03 2017-12-22 동국제약 주식회사 도네페질을 포함하는 비경구투여용 약제학적 조성물
KR101961848B1 (ko) * 2016-08-25 2019-03-25 영진약품 주식회사 C18:1, c18:1(oh) 또는 c18:2의 장쇄 지방산이 포함된 오일류를 포함한 방출억제제를 적용한 서방출성 마이크로스피어 및 이의 제조방법
KR101900482B1 (ko) * 2017-01-17 2018-09-19 한국화학연구원 미립구형 서방출 주사제 및 그의 제조방법
KR102047983B1 (ko) * 2017-11-30 2019-11-22 주식회사 지투지바이오 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법

Also Published As

Publication number Publication date
EP3998065A1 (en) 2022-05-18
CA3143471A1 (en) 2021-01-21
KR20220044921A (ko) 2022-04-12
KR20210007924A (ko) 2021-01-20
WO2021010719A1 (ko) 2021-01-21
AU2020312361A1 (en) 2022-03-03
KR20210065921A (ko) 2021-06-04
CN114126592A (zh) 2022-03-01
ZA202201465B (en) 2023-11-29
CA3143471C (en) 2023-10-31
US20220257518A1 (en) 2022-08-18
EP3998065A4 (en) 2023-07-12
KR20220112737A (ko) 2022-08-11
AU2020312361B2 (en) 2024-05-09
BR112022000413A2 (pt) 2022-03-03
JP2022541011A (ja) 2022-09-21
JP7437074B2 (ja) 2024-02-22
JP2024010233A (ja) 2024-01-23

Similar Documents

Publication Publication Date Title
AU2020312361B2 (en) Long-lasting formulation containing rivastigmine, and method for preparing same
TW389696B (en) Accelerated release composition containing bromocriptine
RU2408368C2 (ru) Препараты соли бупропиона с модифицированным высвобождением
RU2314810C2 (ru) Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5,8,14-триазатетрацикло[10.3.1.0 (2,11).0(4,9)] гексадека-2( 11),3,5,7,9-пентаена
JP2017222705A5 (es)
IE883679L (en) Controlled release combination of carbidopa/levodopa
JP2015506377A5 (es)
US11607389B2 (en) Delayed release deferiprone tablets and methods of using the same
JPH05213741A (ja) デプレニル／ｌ−ドーパ／カルビドーパ含有の医薬組成物
US20100272794A1 (en) Pharmaceutical composition of memantine
EP2004167A1 (en) Renin inhibitors for the treatment of hypertension
SK11072000A3 (sk) Tiagabínové prostriedky s predĺženým uvoľňovaním so zníženými vedľajšími účinkami
EA042135B1 (ru) Таблетка деферипрона с отсроченным высвобождением и способ ее изготовления
KR101151342B1 (ko) 에페리손 함유 필름코팅정제, 및 이의 제조방법
NZ787785A (en) Delayed release deferiprone tablets and methods of using the same
KR20220110259A (ko) 통증 질환에 사용하기 위한 미르타자핀 및 티자니딘 배합물
JP2020063202A (ja) カフェインおよびヒヨスチアミン含有医薬組成物およびその製造方法
WO2015150948A1 (en) Modified release solid oral pharmaceutical compositions of cyclobenzaprine or a salt thereof
KR20130106023A (ko) 에페리손 함유 필름코팅정제, 및 이의 제조방법